An anonymous reader quotes a report from The Guardian: After decades of "demonization", psychiatrists will be able to prescribe MDMA and psilocybin in Australia from July this year. The Therapeutic Goods Administration made the surprise announcement on Friday afternoon. The drugs will only be allowed to be used in a very limited way, and remain otherwise prohibited, but the move was described as a "very welcome step away from what has been decades of demonization" by Dr David Caldicott, a clinical senior lecturer in emergency medicine at Australian National University.

3,4-methylenedioxy-methamphetamine (MDMA) is commonly known as ecstasy, while psilocybin is a psychedelic commonly found in so-called magic mushrooms. Both drugs were used experimentally and therapeutically decades ago, before being criminalized. Specifically authorized psychiatrists will be able to prescribe MDMA for post-traumatic stress disorder, and psilocybin for treatment-resistant depression. Caldicott said it had become "abundantly clear" that a controlled supply of both MDMA and psilocybin "can have dramatic effects on conditions often considered refractory to contemporary treatment" and would particularly benefit returned service men and women from the Australian defense force. "The safe 're-medicalization' of certain historically illicit drugs is a very welcome step away from what has been decades of demonization," he said.

"In addition to a clear and evolving therapeutic benefit, it also offers the chance to catch up on the decades of lost opportunity [of] delving into the inner workings of the human mind, abandoned for so long as part of an ill-conceived, ideological "war on drugs.'"

As global demand for Covid-19 vaccines dries up, the program responsible for vaccinating the world's poor has been urgently negotiating to try to get out of its deals with pharmaceutical companies for shots it no longer needs. From a report: Drug companies have so far declined to refund $1.4 billion in advance payments for now-canceled doses, according to confidential documents obtained by The New York Times. Gavi, the international immunization organization that bought the shots on behalf of the global Covid vaccination program, Covax, has said little publicly about the costs of canceling the orders. But Gavi financial documents show the organization has been trying to stanch the financial damage. If it cannot strike a more favorable agreement with another company, Johnson & Johnson, it could have to pay still more.

Gavi is a Geneva-based nongovernmental organization that uses funds from donors including the U.S. government and the Bill and Melinda Gates Foundation to provide childhood immunizations to lower-income nations. Early in the pandemic, it was charged with buying Covid vaccinations for the developing world -- armed with one of the largest-ever mobilizations of humanitarian funding -- and began negotiations with the vaccine makers. Those negotiations went badly at the outset. The companies initially shut the organization out of the market, prioritizing high-income countries that were able to pay more to lock up the first doses. [...] The vaccine makers have brought in more than $13 billion from the shots that have been distributed through Covax. Under the contracts, the companies are not obligated to return the prepayments Gavi gave them to reserve vaccines that were ultimately canceled.

Chess experts make more mistakes when air pollution is high, a study has found. From a report: Experts used computer models to analyse the quality of games played and found that with a modest increase in fine particulate matter, the probability that chess players would make an error increased by 2.1 percentage points, and the magnitude of those errors increased by 10.8%. The paper, published in the journal Management Science, studied the performance of 121 chess players in three seven-round tournaments in Germany in 2017, 2018, and 2019, comprising more than 30,000 chess moves.

The researchers compared the actual moves the players made against the optimal moves determined by the powerful chess engine Stockfish. In the tournament venues, the researchers attached three web-connected air quality sensors to measure carbon dioxide, PM2.5 concentrations, and temperature. Each tournament lasted eight weeks, meaning players faced a variety of air conditions. Fine particulate matter, or PM2.5, refers to tiny particles 2.5 microns or less in diameter, which are often expelled by burning matter such as that from car engines, coal plants, forest fires, and wood burners. Further reading: Study Reveals Links Between UK Air Pollution and Mental Ill-Health.

Planting more trees could mean fewer people die from increasingly high summer temperatures in cities, a study suggests. The Guardian reports: Increasing the level of tree cover from the European average of 14.9% to 30% can lower the temperature in cities by 0.4C, which could reduce heat-related deaths by 39.5%, according to first-of-its-kind modeling of 93 European cities by an international team of researchers. [...] The researchers used mortality data to estimate the potential reduction in deaths from lower temperatures as a result of increased tree coverage. Using data from 2015 they estimated that out of the 6,700 premature deaths that year attributed to higher urban temperatures, 2,644 could have been prevented had tree cover been increased.

The cities most likely to benefit from the increase in tree coverage are in south and eastern Europe, where summer temperatures are highest and tree coverage tends to be lower. In Cluj-Napoca in Romania -- which had the highest number of premature deaths due to heat in 2015, at 32 per 100,000 people -- tree coverage is just 7%. In Lisbon, Portugal it is as low as 3.6% and in Barcelona its 8.4%. That compares with 15.5% in London and 34% in Oslo. Study co-author Mark Nieuwenhuijsen, a researcher at the Barcelona Institute for Global Health, said the team picked 30% as that is a target that many cities are currently working towards.

He said there was no need for buildings to be razed and replaced with parks, since there is enough space to plant more trees in all the cities the team looked at. He praised initiatives such as the EU's 3 billion trees plan, and the UK government's proposal to ensure every home is within a 15-minute walk from green space, though he noted that policymakers must ensure trees are evenly distributed between richer and poor neighborhoods. He added that cities which are "too car-dominated" should consider replacing asphalt roads, which absorb heat, with trees. Planting more trees in cities should be prioritized because it brings a huge range of health benefits beyond reducing heat-related deaths, he added, including reducing cardiovascular disease, dementia and poor mental health. The study has been published in the journal The Lancet.

An anonymous reader quotes a report from Wired: Your gut has an obvious job: It processes the food you eat. But it has another important function: It protects you from the bacteria, viruses, or allergens you ingest along with that food. "The largest part of the immune system in humans is the GI tract, and our biggest exposure to the world is what we put in our mouth," says Michael Helmrath, a pediatric surgeon at Cincinnati Children's Hospital Medical Center who treats patients with intestinal diseases. Sometimes this system malfunctions or doesn't develop properly, which can lead to gastrointestinal conditions like ulcerative colitis, Crohn's disease, and celiac -- all of which are on the rise worldwide. Studying these conditions in animals can only tell us so much, since their diets and immune systems are very different from ours.

In search of a better method, last week Helmrath and his colleagues announced in the journal Nature Biotechnology that they had transplanted tiny, three-dimensional balls of human intestinal tissue into mice. After several weeks, these spheres -- known as organoids -- developed key features of the human immune system. The model could be used to mimic the human intestinal system without having to experiment on sick patients. The experiment is a dramatic follow-up from 2010, when researchers at Cincinnati Children's became the first in the world to create a working intestine organoid -- but their initial model was a simpler version in a lab dish. A few years later, Helmrath says, they realized "we needed it to become more like human tissue." [...]

Matthew Grisham, a gastroenterologist at Texas Tech University Health Sciences Center who wasn't involved in the new study, says the findings are exciting because these structures have a "human immune cell composition very similar to that of the developing human gut." He says the organoid model will help researchers investigate the mechanisms responsible for intestinal infection, inflammation, and food allergies. The Cincinnati researchers also hope their organoids could one day be used to treat people born with genetic defects that affect their digestive systems, or those who have lost intestinal function to cancer or inflammatory bowel diseases. That these organoids can flourish in a mouse is an encouraging sign that they might be able to grow on their own if transplanted into a person. Using induced pluripotent stem cells taken from patients, scientists could perhaps one day make customized tissue patches to help heal damaged organs. In the near-term, Helmrath says his team plans on making organoids from patients' own cells to test out possible individualized therapies. "This is right around the corner," he says.

One of the most precise surveys of the structure of the universe has suggested it is "less clumpy" than expected, in findings that could indicate the existence of mysterious forces at work. From a report: The observations by the Dark Energy Survey and the South Pole Telescope chart the distribution of matter with the aim of understanding the competing forces that shaped the evolution of the universe and govern its ultimate fate. The extraordinarily detailed analysis adds to a body of evidence that suggests there may be a crucial component missing from the so-called standard model of physics.

"It seems like there is slightly less [clumpiness] in the current universe than we would predict assuming our standard cosmological model anchored to the early universe," said Eric Baxter, an astrophysicist at the University of Hawaii and co-author of the study. The results did not pass the statistical threshold that scientists consider to be ironclad enough to claim a discovery, but they do come after similar findings from previous surveys that hint a crack could be opening up between theoretical predictions and what is actually going on in the universe. "If the finding stands up it's very exciting," said Dr Chihway Chang, an astrophysicist at the University of Chicago and a lead author. "The whole point of physics is to test models and break them. The best scenario is it helps us understand more about the nature of dark matter and dark energy."

Physicists at MIT have for the very first time observed a resonance between two colliding ultracold molecules. The findings have been published in the journal Nature. From the report: They found that a cloud of super-cooled sodium-lithium (NaLi) molecules disappeared 100 times faster than normal when exposed to a very specific magnetic field. The molecules' rapid disappearance is a sign that the magnetic field tuned the particles into a resonance, driving them to react more quickly than they normally would. The findings shed light on the mysterious forces that drive molecules to chemically react. They also suggest that scientists could one day harness particles' natural resonances to steer and control certain chemical reactions.

Overall, the discovery provides a deeper understanding of molecular dynamics and chemistry. While the team does not anticipate scientists being able to stimulate resonance, and steer reactions, at the level of organic chemistry, it could one day be possible to do so at the quantum scale. "One of the main themes of quantum science is studying systems of increasing complexity, especially when quantum control is potentially in the offing," says John Doyle, professor of physics at Harvard University, who was not involved in the group's research. "These kind of resonances, first seen in simple atoms and then more complicated ones, led to amazing advances in atomic physics. Now that this is seen in molecules, we should first understand it in detail, and then let the imagination wander and think what it might be good for, perhaps constructing larger ultracold molecules, perhaps studying interesting states of matter."

An anonymous reader quotes a report from Gizmodo: Genetic engineering company Colossal Biosciences said Tuesday that it will try to resurrect the extinct dodo bird, and it's received $150 million in new funding to support its "de-extinction" activities. The dodo was already part of Colossal's plans by September 2022, but now the company has announced it with all the pomp, circumstance, and seed funding that suggests it will actually go after that goal. The $150 million, the company's second round of funding, was led by several venture capital firms, including United States Innovative Technology Fund and In-Q-Tel, a VC firm funded by the CIA that first put money into the company in September. Adding the dodo to its official docket brings Colossal's total de-extinction targets to three: the woolly mammoth (the company's first target species, announced in September 2021), and the thylacine, a.k.a. the Tasmanian tiger, the largest carnivorous marsupial. Adding the dodo to its official docket brings Colossal's total de-extinction targets to three: the woolly mammoth (the company's first target species, announced in September 2021), and the thylacine, a.k.a. the Tasmanian tiger, the largest carnivorous marsupial.

Colossal's stated goal is not to simply bring these creatures back for vibes; its contention is that reintroducing the species to their respective habitats would help restore a certain amount of normalcy to those environments. Mammoths died out about 4,000 years ago on Wrangel Island, off the northeastern coast of Russia. The dodo, a species of flightless bird native to the island of Mauritius, was gone by 1681. The last known thylacine died at a zoo in Tasmania in 1936. Scientists have sequenced the genomes of all three species -- the mammoth's in 2015, the dodo's in 2016, and the thylacine's in 2018. The latter species were driven to extinction by humankind; humans hunted the dodo, introduced predators and pests to its environment, and contributed to its habitat loss. Humans may have played a role in mammoth extinction as well, but the dodo and the thylacine are classic examples of our ability to wipe out species at extraordinary speed. [...]

If the company's work pans out -- and that's a big if -- proxy species of those extinct animals will be brought to bear. That's because the genetically engineered animals produced by Colossal would not be a bonafide mammoth, dodo, or thylacine. In 2016, the International Union for Conservation of Nature's Species Survival Commission published a report (PDF) denoting ground rules for creating proxy species. "Proxy is used here to mean a substitute that would represent in some sense (e.g. phenotypically, behaviorally, ecologically) another entity -- the extinct form," the commission stated, adding that "Proxy is preferred to facsimile, which implies creation of an exact copy." De-extinction is something of a misnomer, as this process, if successful, will yield science's best analogue for an extinct creature, not the creature itself as it existed in the past. De-extinction methods generally rely on using a living creature's genetics in the resurrection process. That means any 21st-century mammoth will have at least some modern elephant DNA imbued in it, and any nascent thylacine would be produced from the genome and egg of a related species.

schwit1 shares a report from Ars Technica: More than four months have passed since the launch of Blue Origin's New Shepard rocket ended in failure. No humans were onboard the vehicle because it was conducting a suborbital scientific research mission, but the failure has grounded the New Shepard fleet ever since. The rocket's single main engine failed about one minute into the flight, at an altitude of around 9 km, as it was throttling back up after passing through the period of maximum dynamic pressure. At that point a large fire erupted in the BE-3 engine, and the New Shepard capsule's solid rocket motor-powered escape system fired as intended, pulling the capsule away from the exploding rocket. The capsule experienced high G-forces during this return but appeared to make a safe landing.

Three days after this accident with the New Shepard-23 mission, the bipartisan leadership of the House Subcommittee on Space and Aeronautics sent a letter to the Federal Aviation Administration, calling for a thorough investigation. In an interview with Ars later that month, the chair of the subcommittee, US Rep. Don Beyer (D-Va.), urged Blue Origin to be transparent. "I'm heavily in favor of transparency, and I'm hoping that the FAA comes through pretty quickly with this," Beyer said. "I would strongly encourage Blue Origin to be as transparent as possible, because that builds trust. It doesn't have to be overnight, but it would be nice to keep people updated on the progress they're making." The company has not heeded this advice. An application filed with the FCC last week suggests Blue Origin might target a launch for its next New Shepard flight between April 1 and June 1. However, a spokesperson downplayed that speculation, saying it is not tied to a specific launch. "As a matter of course, we submit rolling FCC license requests to ensure we have continuous coverage for launches," the spokesperson said.

It's also unclear whether this next launch will be an uncrewed or a crewed mission.

Slashdot reader schwit1 adds: "For the time being, the New Space Race is pretty much Elon vs the World."

Impossible Foods, which makes plant-based nuggets, burgers and patties, is reportedly laying off 20% of its staff, Bloomberg reported first. TechCrunch reports: According to the story, the 12-year-old company currently employs about 700 workers, which could then affect over 100 employees. This comes as the company made a 6% reduction in its workforce last October. While we know layoffs can happen anytime, it seems like the company was doing well. Earlier this month, the Redwood City, California-based company reported a year of record sales that included over 50% dollar sales growth in 2022. The company also touted that its Impossible Beef product was "the best-selling product by volume of any plant-based meat brand in the U.S."

Months before that, CEO Peter McGuinness said in an interview with Bloomberg Technology that the company had a strong balance sheet, good cash flow and growth of between 65% to 70%. In total, Impossible raised $1.9 billion in venture capital, according to Crunchbase data. The last time the company raised capital was a $500 million Series H round in November 2021, and it was at that time that the company was valued at $7 billion. [...] Impossible is not the only plant-based meat alternative company to make layoffs in recent months. In a regulatory filing made last October, Beyond Meat said it planned to lay off about 200 employees, or 19% of its workforce, as part of cost-saving measures as sales were slumping.

Satellite navigation systems for lunar settlements will require local atomic clocks. Scientists are working out what time they will keep. From a report: It's not obvious what form a universal lunar time would take. Clocks on Earth and the Moon naturally tick at different speeds, because of the differing gravitational fields of the two bodies. Official lunar time could be based on a clock system designed to synchronize with UTC, or it could be independent of Earth time. Representatives of space agencies and academic organizations worldwide met in November 2022 to start drafting recommendations on how to define lunar time at the European Space Research and Technology Centre of the European Space Agency (ESA) in Noordwijk, the Netherlands.

Decisions must be made soon, says Patrizia Tavella, who leads the time department at the International Bureau of Weights and Measures in Sevres, France. If an official lunar time is not established, space agencies and private companies will come up with their own solutions, she says. "This is why we want to raise an alert now, saying let's work together to take a common decision." The most pressing need for lunar time comes from plans to create a dedicated global satellite navigation system (GNSS) for the Moon, similar to how GPS and other satellite navigation networks enable precise location tracking on Earth.

Space agencies plan to install this lunar GNSS from around 2030. ESA approved a lunar satellite navigation project called Moonlight at its ministerial council meeting on 22 and 23 November 2022 in Paris, and NASA established a similar project, called Lunar Communications Relay and Navigation Systems, last January. Until now, Moon missions have pinpointed their locations using radio signals sent to large antennas on Earth at scheduled times. But with dozens of missions planned, "there's just not enough resources to cover everybody," says Joel Parker, an engineer who works on lunar navigation at the Goddard Center.

The New York Times looks at the AbbVie's anti-inflammatory drug Humira and their "savvy but legal exploitation of the U.S. patent system." Though AbbVie's patent was supposed to expire in 2016, since then it's maintained a monopoly that generated $114 billion in revenue by using "a formidable wall of intellectual property protection and suing would-be competitors before settling with them to delay their product launches until this year." AbbVie did not invent these patent-prolonging strategies; companies like Bristol Myers Squibb and AstraZeneca have deployed similar tactics to maximize profits on drugs for the treatment of cancer, anxiety and heartburn. But AbbVie's success with Humira stands out even in an industry adept at manipulating the U.S. intellectual-property regime.... AbbVie and its affiliates have applied for 311 patents, of which 165 have been granted, related to Humira, according to the Initiative for Medicines, Access and Knowledge, which tracks drug patents. A vast majority were filed after Humira was on the market.

Some of Humira's patents covered innovations that benefited patients, like a formulation of the drug that reduced the pain from injections. But many of them simply elaborated on previous patents. For example, an early Humira patent, which expired in 2016, claimed that the drug could treat a condition known as ankylosing spondylitis, a type of arthritis that causes inflammation in the joints, among other diseases. In 2014, AbbVie applied for another patent for a method of treating ankylosing spondylitis with a specific dosing of 40 milligrams of Humira. The application was approved, adding 11 years of patent protection beyond 2016.

AbbVie has been aggressive about suing rivals that have tried to introduce biosimilar versions of Humira. In 2016, with Amgen's copycat product on the verge of winning regulatory approval, AbbVie sued Amgen, alleging that it was violating 10 of its patents. Amgen argued that most of AbbVie's patents were invalid, but the two sides reached a settlement in which Amgen agreed not to begin selling its drug until 2023.

Over the next five years, AbbVie reached similar settlements with nine other manufacturers seeking to launch their own versions of Humira. All of them agreed to delay their market entry until 2023.
A drug pricing expert at Washington University in St. Louis tells the New York Times that AbbVie and its strategy with Humira "showed other companies what it was possible to do."

But the article concludes that last year such tactics "became a rallying cry" for U.S. lawmakers "as they successfully pushed for Medicare to have greater control over the price of widely used drugs that, like Humira, have been on the market for many years but still lack competition."

segaboy81 shares a report from Neowin: What do you get when the world's largest CRM breaks into the research industry and leverages AI to build their products? You get ProGen, a new AI system that can make artificial enzymes from scratch that can work just as well as real ones found in nature. ProGen was made by Salesforce Research (yes, that Salesforce) and uses language processing to learn about biology. In short, ProGen takes amino acid sequences and turns them into proteins....

"The artificial designs are better than ones made by the normal process," said James Fraser, a scientist involved in the project. "We can now make specific types of enzymes, like ones that work well in hot temperatures or acid."

To make ProGen, the scientists at Salesforce fed the system amino acid sequences from 280 million different proteins. The AI system quickly made a staggering one million protein sequences, of which 100 were picked to test. Out of these, five were made into actual proteins and tested in cells. That's just 0.0005% of the generated results....

The code for ProGen is available on Github for anyone who wants to try it (or add to it)
The project shows "how generative AI can lead to potential solutions for addressing challenges in human disease and the environment," argues a statement form Salesforce.

More details from New Scientist: The AI, called ProGen, works in a similar way to AIs that can generate text. ProGen learned how to generate new proteins by learning the grammar of how amino acids combine to form 280 million existing proteins. Instead of the researchers choosing a topic for the AI to write about, they could specify a group of similar proteins for it to focus on. In this case, they chose a group of proteins with antimicrobial activity.

The researchers programmed checks into the AI's process so it wouldn't produce amino acid "gibberish", but they also tested a sample of the AI-proposed molecules in real cells. Of the 100 molecules they physically created, 66 participated in chemical reactions similar to those of natural proteins that destroy bacteria in egg whites and saliva. This suggested that these new proteins could also kill bacteria. The researchers selected the five proteins with the most intense reactions and added them to a sample of Escherichia coli bacteria. Two of the proteins destroyed the bacteria.

The researchers then imaged them with X-rays. Even though their amino acid sequences were up to 30% different from any existing proteins, their shapes almost matched naturally occurring proteins. James Fraser at the University of California, San Francisco, who was part of the team, says it was not clear from the outset that the AI could work out how to change the amino acid sequence so much and still produce the correct shape.... He was surprised to have found a well-functioning protein in the first relatively small fraction of all the ProGen-generated proteins that they tested.

Researchers from the University of Birmingham have developed an innovative method for existing furnaces that could reduce steelmaking's CO2 emission by nearly 90%. The Next Web reports: The iron and steel industry is a major cause of greenhouse gasses, accounting for 9% of global emissions. That's because of the inherent carbon-intensive nature of steel production in blast furnaces, which currently represent the most-widely used practice. In blast furnace steel manufacturing, coke (a type of coal) is used to produce metallic iron from ore obtained from mining -- which releases large quantities of carbon dioxide in the process. According to Dr Harriet Kildahl, who co-devised the method with Professor Yulong Ding, their technology aims to convert this carbon dioxide into carbon monoxide that can be reused in the iron ore reaction.

This is realized using a thermochemical cycle which performs chemical reactions through changes in temperature. That way, the typically damaging CO2 is turned into a useful part of the reaction, forming "an almost perfect closed carbon loop." This drastically reduces emission by the amount of coke needed and, subsequently, lowers steelmaking's emissions by up to 88%. As per the researchers, if this method was implemented in the remaining two blast furnaces in the UK, it could save 1.28 billion pounds in 5 years, all while reducing the country's overall emissions by 2.9%.

"Current proposals for decarbonizing the steel sector rely on phasing out existing plants and introducing electric arc furnaces powered by renewable electricity. However, an electric arc furnace plant can cost over 1 billion pounds to build, which makes this switch economically unfeasible in the time remaining to meet the Paris Climate Agreement," Professor Ding said. "The system we are proposing can be retrofitted to existing plants, which reduces the risk of stranded assets, and both the reduction in CO2, and the cost savings, are seen immediately." The study has been published in the Journal of Cleaner Production.

An anonymous reader quotes a report from MIT Technology Review: Eight years ago, a patient lost her power of speech because of ALS, or Lou Gehrig's disease, which causes progressive paralysis. She can still make sounds, but her words have become unintelligible, leaving her reliant on a writing board or iPad to communicate. Now, after volunteering to receive a brain implant, the woman has been able to rapidly communicate phrases like "I don't own my home" and "It's just tough" at a rate approaching normal speech. That is the claim in a paper published over the weekend on the website bioRxiv by a team at Stanford University. The study has not been formally reviewed by other researchers. The scientists say their volunteer, identified only as "subject T12," smashed previous records by using the brain-reading implant to communicate at a rate of 62 words a minute, three times the previous best. [...] People without speech deficits typically talk at a rate of about 160 words a minute. Even in an era of keyboards, thumb-typing, emojis, and internet abbreviations, speech remains the fastest form of human-to-human communication.

The brain-computer interfaces that [co-lead author Krishna Sehnoy's] team works with involve a small pad of sharp electrodes embedded in a person's motor cortex, the brain region most involved in movement. This allows researchers to record activity from a few dozen neurons at once and find patterns that reflect what motions someone is thinking of, even if the person is paralyzed. In previous work, paralyzed volunteers have been asked to imagine making hand movements. By "decoding" their neural signals in real time, implants have let them steer a cursor around a screen, pick out letters on a virtual keyboard, play video games, or even control a robotic arm. In the new research, the Stanford team wanted to know if neurons in the motor cortex contained useful information about speech movements, too. That is, could they detect how "subject T12" was trying to move her mouth, tongue, and vocal cords as she attempted to talk?

These are small, subtle movements, and according to Sabes, one big discovery is that just a few neurons contained enough information to let a computer program predict, with good accuracy, what words the patient was trying to say. That information was conveyed by Shenoy's team to a computer screen, where the patient's words appeared as they were spoken by the computer. [...] The current system already uses a couple of types of machine learning programs. To improve its accuracy, the Stanford team employed software that predicts what word typically comes next in a sentence. "I" is more often followed by "am" than "ham," even though these words sound similar and could produce similar patterns in someone's brain. Adding the word prediction system increased how quickly the subject could speak without mistakes.

The publishers of thousands of scientific journals have banned or restricted contributors' use of an advanced AI-driven chatbot amid concerns that it could pepper academic literature with flawed and even fabricated research. From a report: ChatGPT, a fluent but flaky chatbot developed by OpenAI in California, has impressed or distressed more than a million human users by rattling out poems, short stories, essays and even personal advice since its launch in November. But while the chatbot has proved a huge source of fun -- its take on how to free a peanut butter sandwich from a VCR, in the style of the King James Bible, is one notable hit -- the program can also produce fake scientific abstracts that are convincing enough to fool human reviewers. ChatGPT's more legitimate uses in article preparation have already led to it being credited as a co-author on a handful of papers.

The sudden arrival of ChatGPT has prompted a scramble among publishers to respond. On Thursday, Holden Thorp, the editor-in-chief of the leading US journal Science, announced an updated editorial policy, banning the use of text from ChatGPT and clarifying that the program could not be listed as an author. Leading scientific journals require authors to sign a form declaring that they are accountable for their contribution to the work. Since ChatGPT cannot do this, it cannot be an author, Thorp says. But even using ChatGPT in the preparation of a paper is problematic, he believes. ChatGPT makes plenty of errors, which could find their way into the literature, he says, and if scientists come to rely on AI programs to prepare literature reviews or summarise their findings, the proper context of the work and the deep scrutiny that results deserve could be lost. "That is the opposite direction of where we need to go," he said. Other publishers have made similar changes. On Tuesday, Springer-Nature, which publishes nearly 3,000 journals, updated its guidelines to state that ChatGPT cannot be listed as an author. But the publisher has not banned ChatGPT outright. The tool, and others like it, can still be used in the preparation of papers, provided full details are disclosed in the manuscript.

A wearable ultrasound imager for the heart that is roughly the size of a postage stamp, can be worn for up to 24 hours, and works even during exercise may one day help doctors spot cardiac problems that current medical technology might miss, a new study finds. IEEE Spectrum reports: Now scientists have developed a wearable ultrasound device that can enable safe, continuous, real-time, long-term, and highly detailed imaging of the heart. They detailed their findings online on January 25 in the journal Nature. "Potential applications include continuously monitoring the heart in daily life, during exercise, during surgery, and much more," says study coauthor Ray Wu, a nanoengineer at UC San Diego. "This will open up the possibility to detect previously undetectable symptoms of disease, identify symptoms in their very early stages, and greatly improve patient outcomes."

The new device is a patch 1.9 centimeters long by 2.2 cm wide and only 0.9 millimeters thick. It uses an array of piezoelectric transducers to send and receive ultrasound waves in order to generate a constant stream of images of the structure and function of the heart. The researchers were able to get such images even during exercise on a stationary bike. No skin irritation or allergy was seen after 24 hours of continuous wear. "The most exciting result is that our patch performs well when an individual is moving," Hu says. "Our patch allows us to evaluate heart performance throughout exercise, providing valuable information about the heart when it is under high stress." The new patch is about as flexible as human skin. It can also stretch up to 110 percent of its size, which means it can survive far more strain than typically experienced on human skin. These features help it stick onto the body, something not possible with the rigid equipment often used for cardiac imaging.

In the new study, the researchers focused on imaging the left ventricle, the largest of the heart's four chambers "and strongly considered to be the most important in terms of cardiovascular health, as it is responsible for pumping oxygenated blood to the entire body," Wu says. Cardiac imaging generally focuses on the left ventricle, but the new device can image all of the heart's four chambers simultaneously, "so it may be possible for future research to focus on other or multiple chambers," he adds. In addition, "the imager can be applied to image various other organs, such as the stomach, kidney, or liver." Traditional cardiac ultrasound imaging constantly rotates an ultrasound probe to analyze the heart in multiple dimensions. To eliminate the need for this rotation, the array of ultrasound sensors and emitters in the new device is shaped like a cross so that ultrasonic waves can travel at right angles to each other. The scientists developed a custom deep-learning AI model that can analyze the data from the patch and automatically and continuously estimate vital details, such as the percentage of blood pumped out of the left ventricle with each beat, and the volume of blood the heart pumps out with each beat and every minute. The root of most heart problems is the heart not pumping enough blood, issues that often manifest only when the body is moving, the researchers note.

A small asteroid is flying very close to Earth on Thursday night, less than a week after astronomers discovered the object. The New York Times reports: The asteroid, named 2023 BU, was scheduled to pass over the southern tip of South America at 7:27 p.m. Eastern time. The asteroid is fairly small -- less than 30 feet across, about the size of a truck -- and will be best visible in the skies to the west of southern Chile. For space watchers unable to view 2023 BU firsthand, the Virtual Telescope Project will be broadcasting the event on its website and YouTube channel. The asteroid will not hit Earth but will make one of the closest approaches ever by such an object, hurtling past Earth at just 2,200 miles above its surface, according to a news release from the NASA Jet Propulsion Laboratory. This encounter puts the asteroid "well within the orbit of geosynchronous satellites," the statement noted, but the asteroid is not on track to hit any.

2023 BU was unknown to NASA, or anyone, until last Saturday. Gennadiy Borisov, an amateur astronomer in Crimea, noticed the asteroid from the MARGO Observatory, a setup of telescopes that he has used to discover other interstellar objects. Astronomers then determined 2023 BU's orbit around the sun and impending trip past Earth using data from the Minor Planet Center, a project sanctioned by the International Astronomical Union. It publishes positions of newly found space objects, including comets and satellites, from information of several observatories worldwide.

Scientists from the U.S. National Institutes of Health found a link between dozens of different viral exposures and a later increased risk of Alzheimer's disease and other brain disorders. Gizmodo reports: They analyzed data from two existing and nationally representative biobank projects tracking the long-term health of residents in Finland and the UK, respectively, collectively involving around 450,000 people. They looked for links between viral infections that led to hospitalization and six neurodegenerative diseases: Alzheimer's disease (the most common form of dementia), ALS, multiple sclerosis, Parkinson's disease, vascular dementia, and generalized dementia. In the Finland data, they initially identified 45 types of viral exposure potentially linked to a greater risk of neurodegenerative illness. To double-check these results, they then ran the same sort of analysis on the UK data and found a similar relationship for 22 types of viral exposure across both datasets.

Some of these exposures involved specific viral infections, such as influenza, varicella zoster virus (the cause of chickenpox and shingles), and herpes simplex viruses. Others concerned where an infection or its harmful effects took place, such as viral encephalitis or meningitis, types of brain inflammation that can be caused by many different viruses. For some exposures, the risk of subsequent brain illness extended up to 15 years later, while the strongest link was seen between viral encephalitis and Alzheimer's. The team's findings were published earlier this month in Neuron. "As vaccines are currently available for some of the associated viruses, vaccination may be a way to reduce some risk of neurodegenerative disease," the authors note.

On Monday, SpaceX fueled a fully stacked Starship for the first time. Engadget reports: The "wet dress rehearsal" saw the company load the vehicle's Super Heavy and Starship stages with more than 10 million pounds of liquid oxygen and methane fuel. Additionally, SpaceX ran through some of the countdown procedures it will need to complete on launch day. "Today's test will help verify a full launch countdown sequence, as well as the performance of Starship and the orbital pad for flight-light operations," SpaceX posted on Twitter. As Space.com notes, Monday's test means SpaceX is on track to complete an orbital flight of Starship sometime in the coming months.